Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback